- Home
- ETNB vs PHVS Comparison
ETNB vs PHVS Comparison
Compare ETNB & PHVS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ETNB
- PHVS
- Stock Information
- Founded
- ETNB 2018
- PHVS 2015
- Country
- ETNB United States
- PHVS Switzerland
- Employees
- ETNB N/A
- PHVS N/A
- Industry
- ETNB Biotechnology: Pharmaceutical Preparations
- PHVS Biotechnology: Pharmaceutical Preparations
- Sector
- ETNB Health Care
- PHVS Health Care
- Exchange
- ETNB Nasdaq
- PHVS Nasdaq
- Market Cap
- ETNB 1.5B
- PHVS 1.3B
- IPO Year
- ETNB 2019
- PHVS 2021
- Fundamental
- Price
- ETNB $8.08
- PHVS $24.08
- Analyst Decision
- ETNB Strong Buy
- PHVS Strong Buy
- Analyst Count
- ETNB 10
- PHVS 5
- Target Price
- ETNB $27.22
- PHVS $35.60
- AVG Volume (30 Days)
- ETNB 1.3M
- PHVS 123.2K
- Earning Date
- ETNB 11-06-2025
- PHVS 11-12-2025
- Dividend Yield
- ETNB N/A
- PHVS N/A
- EPS Growth
- ETNB N/A
- PHVS N/A
- EPS
- ETNB N/A
- PHVS N/A
- Revenue
- ETNB N/A
- PHVS N/A
- Revenue This Year
- ETNB N/A
- PHVS N/A
- Revenue Next Year
- ETNB N/A
- PHVS N/A
- P/E Ratio
- ETNB N/A
- PHVS N/A
- Revenue Growth
- ETNB N/A
- PHVS N/A
- 52 Week Low
- ETNB $4.16
- PHVS $11.51
- 52 Week High
- ETNB $11.84
- PHVS $26.33
- Technical
- Relative Strength Index (RSI)
- ETNB 35.99
- PHVS 58.67
- Support Level
- ETNB $7.84
- PHVS $23.20
- Resistance Level
- ETNB $9.47
- PHVS $24.02
- Average True Range (ATR)
- ETNB 0.45
- PHVS 1.37
- MACD
- ETNB -0.08
- PHVS 0.04
- Stochastic Oscillator
- ETNB 13.96
- PHVS 78.51
About ETNB 89bio Inc.
89bio Inc is a United States-based clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its product candidate, pegozafermin (previously BIO89-100), a specifically engineered glycoPEGylated analog of fibroblast growth factor 21 (FGF21), is currently being developed for the treatment of nonalcoholic steatohepatitis (NASH) and for the treatment of severe hypertriglyceridemia (SHTG).
About PHVS Pharvaris N.V.
Pharvaris NV is a late-stage biopharmaceutical company which is engaged in developing novel, oral bradykinin B2 receptor antagonists to prevent and treat HAE attacks. By directly pursuing this clinically therapeutic target with novel small molecules, With positive data in both Phase 2 prophylaxis and studies in HAE, Pharvaris is developing deucrictibant. Pharvaris is currently enrolling a pivotal Phase 3 study for the treatment of HAE attacks and plans to initiate a pivotal Phase 3 study of deucrictibant for the prevention of HAE attacks.